Table 1.

Demographic Data for Patients with Serum Data Utilized in this Pilot Study

Patient	Tx Assignment	Male/ Female	Age at Diagnosis	Location of Primary Tumor	Tumor Stage
1	Erlotinib	Male	57	Hypopharynx	IVa
2	Erlotinib	Female	65	Oral Cavity	IVa
3	Erlotinib	Male	59	Oral Cavity	III
4	Erlotinib	Male	68	Oral Cavity	II
5	Erlotinib	Male	66	Oral Cavity	IVa
9	Erlotinib	Male	67	Larynx	III
13	Erlotinib	Male	64	Tonsil	II
15	Erlotinib	Female	65	Larynx	III
16	Erlotinib	Female	61	Oral Cavity	IVa
23	Erlotinib	Male	46	Oral Cavity	IVa
6	Erlotinib + Sulindac	Male	58	Oral Cavity	III
7	Erlotinib + Sulindac	Male	59	Oral Cavity	IVa
8	Erlotinib + Sulindac	Male	53	Oral Cavity	III
14	Erlotinib + Sulindac	Male	56	Oral Cavity	II
17	Erlotinib + Sulindac	Male	64	Oral Cavity	III
20	Erlotinib + Sulindac	Female	57	Oral Cavity	III
21	Erlotinib + Sulindac	Male	51	Oral Cavity	IVa
22	Erlotinib + Sulindac	Male	64	Oral Cavity	IV
10	Placebo	Male	57	Oral Cavity	IV
11	Placebo	Male	33	Oral Cavity	III
12	Placebo	Female	75	Oral cavity	III
18	Placebo	Male	61	Oral cavity	II
19	Placebo	Female	46	Oropharynx	II